Related Experiment Video

Updated: Aug 22, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.3K

Chronic active Epstein-Bar virus infection complicated by pulmonary artery hypertension

Yukiko Misaki1, Daisuke Minakata2, Tatsuro Ibe3

  • 1Division of Hematology, Jichi Medical University Saitama Medical Center, Japan.

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
|November 14, 2022
PubMed

Insights

Chronic active Epstein-Bar virus infection (CAEBV) can lead to pulmonary artery hypertension (PAH). Treating PAH with vasodilators and CAEBV with chemotherapy improved patient outcomes, suggesting a link between EBV vasculitis and PAH.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Pathology

Background:

  • Chronic active Epstein-Bar virus infection (CAEBV) presents with diverse symptoms.
  • Pulmonary artery hypertension (PAH) is a known cardiovascular complication of CAEBV, but its mechanisms and treatment efficacy remain unclear.

Observation:

  • This study details 4 adult patients with CAEBV and concurrent PAH.
  • Patients received vasodilator therapy for PAH, followed by chemotherapy (with or without stem cell transplantation) for CAEBV.

Findings:

  • Transtricuspid pressure gradient improved with vasodilators in all patients.
  • Three patients showed further improvement after CAEBV-directed treatment.
  • Autopsies revealed Epstein-Barr virus-encoded small RNA (EBER)-positive cells and pulmonary artery pathology, indicating EBV-driven vasculitis.

Implications:

  • Epstein-Barr virus-infected cells can induce vasculitis, leading to PAH.
  • PAH associated with CAEBV is potentially treatable with both PAH-specific medications and CAEBV therapies.

Keywords:
Adult patientsCAEBVCAEBV complicationPAHPH

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.0K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
234
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
265
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
29
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K